On April 29, 2014, the Food and Drug Administration (FDA) approved the use of ceritinib for the treatment of ALK-positive metastatic NSCLC patients who are intolerant to crizotinib or have progressed after crizotinib treatment. The gene discussed is ALK; the disease is non-small cell lung carcinoma.